Androgen Receptor and Hair Follicle Research Compounds: An Overview

Research use only. The compounds discussed here are laboratory reagents supplied strictly for in vitro and scientific research. They are not medicines, not dietary supplements, and not intended for human or veterinary use, consumption, or administration of any kind. Nothing below is a health claim or a usage instruction.

Hair follicle biology is one of the older and better characterised corners of experimental dermatology. Because the follicle is a small, cyclically regenerating mini organ that can be dissected, cultured and imaged, it became a favourite model system for studying androgen signalling, vascular growth factors, potassium channel pharmacology and stem cell niches. A cluster of research compounds grew up around that literature, and researchers working in dermatological and endocrine models frequently encounter the same handful of names.

This overview describes what the preclinical literature has examined for the main compound classes in this category, how they are studied at the bench, and what the regulatory picture looks like in the European Union. It is a map of the research landscape, not a guide to using anything.

What are androgen receptor and hair follicle research compounds

The term is an umbrella for chemically unrelated substances that share a common experimental context: they have been studied in models of the hair follicle, the dermal papilla, or androgen receptor signalling in skin tissue. They fall into three broad groups.

Nonsteroidal androgen receptor antagonists. Compounds such as RU-58841 bind the androgen receptor without activating it, competing with dihydrotestosterone at the ligand binding domain. They were originally designed in the search for antiandrogens that act locally in skin rather than systemically.

Potassium channel openers. Minoxidil is the archetype. It is a vasodilator whose activity in follicle biology has been attributed to ATP sensitive potassium channels and to downstream signalling in dermal papilla cells rather than to any hormonal action.

Matrix and copper binding peptides. GHK-Cu, the copper tripeptide glycyl-L-histidyl-L-lysine, entered this literature from a different direction. It was first characterised as a plasma factor influencing cultured cells, and later studied in extracellular matrix, angiogenesis and gene expression models. Our separate write-up on GHK-Cu copper peptide research covers that background in more depth.

Where these compounds sit in the research literature

Preclinical work in this area is dominated by three model systems: cultured human dermal papilla cells, whole follicle organ culture, and animal models of androgen dependent hair change, most notably the stumptailed macaque. Reported preclinical areas of investigation include the following.

Reported preclinical areas of investigation

• Androgen receptor transcriptional activity. Cotransfection assays in prostate cancer cell lines have been used to measure whether a candidate compound suppresses dihydrotestosterone driven reporter activity, and to compare its potency against reference antiandrogens such as hydroxyflutamide and bicalutamide.
• Local versus systemic activity. Animal studies have examined whether topically applied antiandrogens produce measurable effects in skin tissue without detectable systemic endocrine changes, a design question that motivated much of the original medicinal chemistry.
• ATP sensitive potassium channel expression. Molecular and immunohistological work has mapped which sulfonylurea receptor and inward rectifier subunits are expressed in the epithelial matrix, dermal papilla and dermal sheath of human follicles.
• Growth factor signalling in dermal papilla cells. In vitro studies have examined intracellular calcium changes and vascular endothelial growth factor production in cultured cells, and the role of adenosine receptor subtypes as intermediates.
• Extracellular matrix and gene expression. Copper peptide research has looked at collagen and glycosaminoglycan synthesis in fibroblast culture and at broad transcriptional profiling in cell lines.
• Follicle cycling in organ culture. Isolated follicles maintained in defined media allow researchers to track the anagen phase and to test whether channel blockers and openers oppose one another.

Two points are worth stressing. First, most of this literature is in vitro or in animal models, and findings in those systems do not transfer automatically to any other context. Second, the mechanistic picture is still incomplete. The paper cited below on potassium channels in human follicles was published in 2008 and explicitly notes that the mechanism of minoxidil remained unclear despite decades of study.

Chemistry and notes at a glance

RU-58841. A nonsteroidal imidazolidine derivative, molecular formula C17H18F3N3O4, molar mass approximately 385.3 g/mol. It is a small lipophilic molecule, poorly soluble in water and typically handled in ethanol or propylene glycol based laboratory solvents. Chemically it belongs to the same nilutamide related family as several oncology antiandrogens.

Minoxidil. A pyrimidine derivative, C9H15N5O, molar mass approximately 209.3 g/mol. In tissue it is converted to minoxidil sulfate, which is the species generally considered active at the potassium channel. It is sparingly soluble in water and more soluble in alcohols.

GHK-Cu. A copper complexed tripeptide, glycyl-L-histidyl-L-lysine plus a copper(II) ion, molar mass approximately 340.8 g/mol for the complex. It is water soluble, distinctly blue in solution, and sensitive to pH and to competing chelators. Reference material is normally supplied lyophilised.

Analytical identity for any of these should be confirmed against a certificate of analysis. Our guide to peptide purity and the certificate of analysis explains what HPLC purity, peptide content and mass spectrometry identity each tell you, and why they are not interchangeable numbers.

Why the research use only label matters

In the European Union, a substance is classified by how it is presented as much as by what it is. A chemical sold and described as a laboratory reagent under REACH is a reagent. The same chemical presented with a therapeutic claim, a human dose, or an administration instruction becomes an unauthorised medicinal product under Directive 2001/83/EC, and both the seller and the listing fall under medicines law. That is why every description on this site is written in the third person about published preclinical work and never about people.

Regulatory and safety status

This category carries some specific flags that researchers should know about.

• RU-58841 was never approved anywhere. Development was discontinued and it has no marketing authorisation in the EU, the United States, or any other jurisdiction we are aware of. There is no completed late stage clinical safety dataset for it. It exists as an investigational reference compound only.
• Minoxidil holds an approval only in specific licensed formulations. Approved topical and oral minoxidil products exist as regulated medicines. Bulk minoxidil supplied as a research chemical is not one of those products, is not equivalent to them, and carries none of their authorisations. Minoxidil is a systemic vasodilator and is treated as a hazardous substance in laboratory handling.
• GHK-Cu is not an approved medicine in the EU. It appears in cosmetic ingredient inventories in some jurisdictions, which is a separate regulatory track from medicinal authorisation and does not imply either.
• None of these compounds is on a WADA prohibited list as of this writing, but doping status changes annually and is not the same thing as safety or legality.

None of the above should be read as an assessment of whether anything here is safe. It is a description of regulatory status, which is a different question entirely.

Handling and storage for researchers

These are ordinary laboratory reagents and follow ordinary laboratory practice.

• Lyophilised peptide material such as GHK-Cu is generally stored sealed at minus 20 degrees Celsius, protected from light and moisture, and allowed to reach room temperature before the vial is opened so that condensation does not settle on the powder.
• Reconstituted peptide solutions are far less stable than the dry form. They are usually kept refrigerated, used within a short working window, and aliquoted so that repeated freeze and thaw cycles are avoided. Copper complexes are additionally sensitive to chelating buffers.
• Small molecules in solvent such as RU-58841 in ethanol or propylene glycol should be stored in tightly closed, solvent compatible containers away from light and heat, with the solvent evaporation rate kept in mind for open handling.
• Capsule and tablet format reference material is kept dry and at room temperature unless the certificate of analysis specifies otherwise, and remains in its labelled container so that identity is never in doubt.
• Documentation. Log lot number, receipt date, reconstitution date and solvent for every vial. Undocumented material is not usable data.

For a fuller treatment of stability, temperature and freeze and thaw behaviour, see our peptide storage and stability laboratory guide.

Frequently asked questions

Is RU-58841 an approved medicine anywhere?

No. RU-58841 has never received marketing authorisation in the European Union or elsewhere. Its clinical development programme was discontinued, so there is no completed regulatory safety review for it. It is available only as a reference compound for laboratory research.

Is it legal to buy these compounds for research in the EU?

Research chemicals in this category are generally supplied as laboratory reagents under REACH, which is legally distinct from medicines regulation. That framing only holds when the material is sold, described and used strictly for research, without therapeutic claims or human use. National rules differ between member states and can change, so the buyer is responsible for confirming the position in their own country and institution before ordering.

Why is minoxidil discussed alongside an androgen receptor antagonist?

Because they occupy the same experimental literature rather than the same mechanism. Antiandrogens are studied for their action at the androgen receptor, while minoxidil is studied through ATP sensitive potassium channels and downstream signalling in dermal papilla cells. Researchers group them by model system, not by pharmacological class.

What does the copper in GHK-Cu actually do in these studies?

In published in vitro work the copper(II) ion is treated as part of the active species rather than an inert counter ion, and the peptide is understood to act as a carrier that modulates copper availability to cells. This is one reason chelating buffers and competing metal ions are a real variable in experimental design.

Do preclinical findings in follicle models transfer to other systems?

Not reliably. Organ culture and animal models are chosen because they are tractable, not because they are perfectly predictive. Species differences in androgen metabolism and in follicle architecture are substantial, and results are treated as hypothesis generating within the model where they were obtained.

Key takeaways

• This cluster groups chemically unrelated compounds by shared experimental context: androgen receptor signalling and hair follicle biology models.
• Nonsteroidal antiandrogens, potassium channel openers and copper binding peptides have all been examined in dermal papilla culture, follicle organ culture and animal models.
• RU-58841 has no marketing authorisation anywhere and no completed late stage clinical safety dataset.
• Bulk minoxidil as a research chemical is not the same thing as an authorised minoxidil medicine and carries none of its approvals.
• All material in this category is supplied for research use only, and should be handled, stored and documented as ordinary laboratory reagents.

Related reading on this site: RU-58841: what the research shows and GHK-Cu and minoxidil: understanding the research combination. Reference material in this category, including the GHK-Cu and minoxidil research capsules and standalone GHK-Cu 100mg, is listed with batch documentation. Compounds not currently listed as active can be found in our full research catalogue.

References

References sourced via PubMed.

1. Pan HJ, Wilding G, Uno H, Inui S, Goldsmith L, Messing E, Chang C. Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques. Endocrine, 1998. DOI | PubMed
2. Shorter K, Farjo NP, Picksley SM, Randall VA. Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil. FASEB Journal, 2008. DOI | PubMed
3. Li M, Marubayashi A, Nakaya Y, Fukui K, Arase S. Minoxidil-induced hair growth is mediated by adenosine in cultured dermal papilla cells: possible involvement of sulfonylurea receptor 2B as a target of minoxidil. Journal of Investigative Dermatology, 2001. DOI | PubMed

Research use only. Not for human or veterinary use. The compounds described on this page are laboratory reagents intended solely for in vitro and scientific research by qualified personnel. Nothing on this page is medical advice, a therapeutic claim, or an instruction for use. Pure Chems makes no representation that any compound discussed is safe or effective for any purpose in humans or animals.